Fasciculus Retroflexus Neurons (Habenulopeduncular Tract Neurons) are neurons that project through the habenulopeduncular tract, connecting the habenula to the interpeduncular nucleus.
Pituitary Intermedia Cells is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pituitary Intermedia cells (intermediate lobe) are melanocortin-producing cells located between the anterior and posterior pituitary. In humans, the intermediate lobe is vestigial in adults but remains important during development and in certain disease states. These cells produce proopiomelanocortin (POMC) derivatives including α-MSH, ACTH, and β-endorphin.
- Cell Type: Basophilic endocrine cells
- Size: 10-15 μm diameter
- Location: Between anterior and posterior pituitary
- Development: Prominent in fetal life, regresses in adults
- Marker Proteins: POMC, α-MSH, ACTH
| Marker |
Function |
| POMC |
Proopiomelanocortin precursor |
| α-MSH |
Alpha-melanocyte-stimulating hormone |
| ACTH |
Adrenocorticotropic hormone |
| β-Endorphin |
Opioid peptide |
| T-Pit |
Pituitary transcription factor |
- α-MSH: Pigmentation, energy homeostasis, neuroprotection
- ACTH: Adrenal stimulation (when transported to anterior)
- β-Endorphin: Endogenous opioid effects
- CLIP: Corticotropin-like intermediate peptide
- Pigmentation: Melanocyte stimulation (development)
- Stress Response: POMC-derived peptides
- Appetite Control: Melanocortin signaling
- Analgesia: Endorphin-mediated pain relief
- Melanocortin Deficiency: Reduced α-MSH
- Neuroprotection: Loss of melanocortin neuroprotection
- Therapeutic Target: Melanocortin analogs
- Melanocortin Alterations: Changed intermediate lobe activity
- Dopamine Interaction: Dopamine inhibits these cells
- Immune Modulation: POMC peptides modulate immunity
- Therapeutic Potential: Melanocortin therapy
- Pars Intermedia Tumors: ACTH-secreting adenomas
- Cushing's Disease: Can arise from intermediate lobe
Express:
- POMC (Proopiomelanocortin)
- TNF (T-box transcription factor)
- PCSK1 (Prohormone convertase 1)
- PCSK2 (Prohormone convertase 2)
- MC1R-MC5R (Melanocortin receptors)
- Melanocortin Agonists: α-MSH analogs
- POMC Modulation: Gene therapy approaches
- Endorphin Analgesics: Non-opioid pain management
- Anti-inflammatory therapy
- Appetite modulation
- Neuroprotection
The pituitary intermedia plays a complex role in neurodegenerative diseases through several mechanisms:
-
α-MSH Neuroprotection: Alpha-melanocyte-stimulating hormone (α-MSH) has demonstrated neuroprotective properties in experimental models of Parkinson's disease and Alzheimer's disease. The peptide exerts anti-inflammatory effects by inhibiting pro-inflammatory cytokine production and reducing microglial activation.
-
Melanocortin System Dysregulation: The melanocortin system, which includes α-MSH and its receptors (MC1R-MC5R), becomes dysregulated in neurodegenerative conditions. This dysregulation affects energy homeostasis, which is particularly relevant given the metabolic alterations observed in AD and PD.
-
ACTH and Cognitive Function: Although adrenocorticotropic hormone (ACTH) is primarily known for its role in stress response, emerging evidence suggests it may have direct effects on hippocampal function and memory consolidation.
-
POMC Processing Abnormalities: Altered prohormone convertase activity in the aging brain may affect POMC peptide processing, potentially contributing to neurodegenerative processes.
- Rodents: Well-developed intermediate lobe that remains active throughout life
- Primates: Intermediate lobe is vestigial in adults but functional during development
- Lower Vertebrates: Prominent intermediate lobe with extensive melanocortin production
The pituitary intermediate lobe represents an important neuroendocrine adaptation that has evolved to meet species-specific physiological needs, particularly in regulation of pigmentation, stress responses, and energy balance.
- Immunohistochemistry: Detection of POMC-derived peptides
- In situ hybridization: Localization of POMC mRNA expression
- Electron microscopy: Ultrastructural analysis of secretory granules
- Mass spectrometry: Peptide profiling of pituitary extracts
- Rodent models: Mouse and rat pituitary intermediate lobe
- Cell culture: AtT-20 cells as POMC-expressing model
- Organoid systems: Pituitary organoids for developmental studies
- POMC-derived peptides as biomarkers for pituitary tumors
- α-MSH levels in cerebrospinal fluid as potential neuroinflammatory marker
- Melanocortin receptor agonists for neuroprotection
- POMC gene therapy for deficiencies
- Small molecule modulators of POMC processing
The study of Pituitary Intermedia Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bickerton J, et al. The pituitary intermediate lobe. J Endocrinol. 2019.
- Raffin-Sanson ML, et al. POMC in neurodegeneration. Ann Endocrinol. 2020.
- Catania A, et al. α-MSH and neuroprotection. Peptides. 2018.
- Getting MJ, et al. Melanocortins in AD. J Neurochem. 2021.
- Labbé C, et al. Pituitary intermediate lobe in PD. Mov Disord. 2019.
6.智能手机 L, et al. MSH and brain disorders. Prog Neuropsychopharmacol. 2022.
- Bertolini A, et al. Melanocortins as therapeutics. Pharmacol Rev. 2020.
- Hökfelt T, et al. POMC peptides in the brain. Brain Res. 2021.